View More Recent Stories
-
JMP Securities Biotechnology Overview
-
Kura Oncology (KURA) Announces Senior Executive Promotions
-
Kura Oncology (KURA) and Kyowa Kirin Report Positive Combination Data for Ziftomenib at American Society of Hematology Annual Meeting
-
Kura Oncology (KURA) PT Lowered to $11 at Stifel
-
TD Cowen Reiterates Buy Rating on Kura Oncology (KURA)
-
Kura Oncology (KURA) PT Raised to $37 at H.C. Wainwright
-
Kura Oncology (KURA) PT Lowered to $28 at Jefferies
-
Kura Oncology (KURA) and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias
-
H.C. Wainwright Reiterates Buy Rating on Kura Oncology (KURA)
-
Kura Oncology (KURA) Reports In-Line Q3 EPS
-
Kura Oncology (KURA) to Present Updated Data from KOMET-007 Combination Trial of Ziftomenib at ASH Annual Meeting
-
H.C. Wainwright Reiterates Buy Rating on Kura Oncology (KURA)
-
UBS Starts Kura Oncology (KURA) at Buy
-
Stifel Downgrades Kura Oncology (KURA) to Hold
-
Kura Oncology (KURA) Appoints Michael Vasconcelles to its Board
-
Kura Oncology (KURA) Tops Q2 EPS by 4c
-
Kura Oncology (KURA) Announces FDA Clearance of IND Application for Menin Inhibitor Ziftomenib in Advanced Gastrointestinal Stromal Tumors
-
H.C. Wainwright Reiterates Buy Rating on Kura Oncology (KURA)
-
Kura Oncology (KURA) Reports Preclinical Data Supporting Potential for Menin Inhibitor in Diabetes
-
Treatment of Blood Cancers - Biopharma Companies Building out their Pipeline of Solutions
-
4 Buy-rated Healthcare stocks with 30-45% upside

